|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Teixeira MR, Kristensen GB, Abeler VM and
Heim S: Karyotypic findings in tumors of the vulva and vagina.
Cancer Genet Cytogenet. 111:87–91. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Micci F, Teixeira MR, Scheistrøen M,
Abeler VM and Heim S: Cytogenetic characterization of tumors of the
vulva and vagina. Genes Chromosomes Cancer. 38:137–148. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Micci F, Panagopoulos I, Haugom L,
Dahlback HS, Pretorius ME, Davidson B, Abeler VM, Tropé CG,
Danielsen HE and Heim S: Genomic aberration patterns and expression
profiles of squamous cell carcinomas of the vulva. Genes
Chromosomes Cancer. 52:551–563. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tcheung WJ, Selim MA, Herndon JE,
Abernethy AP and Nelson KC: Clinicopathologic study of 85 cases of
melanoma of the female genitalia. J Am Acad Dermatol. 67:598–605.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Håvik AB, Lind GE, Honne H, Meling TR,
Scheie D, Hall KS, van den Berg E, Mertens F, Picci P, Lothe RA,
Heim S and Brandal P: Sequencing IDH1/2 glioma mutation hotspots in
gliomas and malignant peripheral nerve sheath tumors. Neuro Oncol.
16:320–322. 2014. View Article : Google Scholar :
|
|
7
|
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda
C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL,
Giovanella BC, et al: TERT promoter mutations occur frequently in
gliomas and a subset of tumors derived from cells with low rates of
self-renewal. Proc Natl Acad Sci USA. 110:6021–6026. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esteller M, Hamilton SR, Burger PC, Baylin
SB and Herman JG: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter
hypermethylation is a common event in primary human neoplasia.
Cancer Res. 59:793–797. 1999.PubMed/NCBI
|
|
9
|
Schoenmakers EF, Wanschura S, Mols R,
Bullerdiek J, Van den Berghe H and Van de Ven WJ: Recurrent
rearrangements in the high mobility group protein gene, HMGI-C, in
benign mesenchymal tumours. Nat Genet. 10:436–444. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hetland TE, Holth A, Kaern J, Flørenes VA,
Tropé CG and Davidson B: HMGA2 protein expression in ovarian serous
carcinoma effusions, primary tumors, and solid metastases. Virchows
Arch. 460:505–513. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiappetta G, Avantaggiato V, Visconti R,
Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti
V, Santoro M, et al: High level expression of the HMGI (Y) gene
during embryonic development. Oncogene. 13:2439–2446.
1996.PubMed/NCBI
|
|
12
|
Rogalla P, Drechsler K, Frey G, Hennig Y,
Helmke B, Bonk U and Bullerdiek J: HMGI-C expression patterns in
human tissues. Implications for the genesis of frequent mesenchymal
tumors. Am J Pathol. 149:775–779. 1996.PubMed/NCBI
|
|
13
|
Geurts JM, Schoenmakers EF and Van de Ven
WJ: Molecular characterization of a complex chromosomal
rearrangement in a pleomorphic salivary gland adenoma involving the
3′-UTR of HMGIC. Cancer Genet Cytogenet. 95:198–205. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mine N, Kurose K, Nagai H, Doi D, Ota Y,
Yoneyama K, Konishi H, Araki T and Emi M: Gene fusion involving
HMGIC is a frequent aberration in uterine leiomyomas. J Hum Genet.
46:408–412. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kazmierczak B, Meyer-Bolte K, Tran KH,
Wöckel W, Breightman I, Rosigkeit J, Bartnitzke S and Bullerdiek J:
A high frequency of tumors with rearrangements of genes of the
HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas.
Genes Chromosomes Cancer. 26:125–133. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nyquist Kb, Panagopoulos I, Thorsen J,
Roberto R, Wik HS, Tierens A, Heim S and Micci F: t(12;13)(q14;q31)
leading to HMGA2 upregulation in acute myeloid leukaemia. Br J
Haematol. 157:769–771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heidenreich B, Rachakonda PS, Hemminki K
and Kumar R: TERT promoter mutations in cancer development. Curr
Opin Genet Dev. 24:30–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel KP, Barkoh BA, Chen Z, Ma D, Reddy
N, Medeiros LJ and Luthra R: Diagnostic testing for IDH1 and IDH2
variants in acute myeloid leukemia an algorithmic approach using
highresolution melting curve analysis. J Mol Diagn. 13:678–686.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wagner K, Damm F, Gohring G, Gorlich K,
Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L, et al:
Impact of IDH1 R132 mutations and an IDH1 single nucleotide
polymorphism in cytogenetically normal acute myeloid leukemia: SNP
rs11554137 is an adverse prognostic factor. J Clin Oncol.
28:2356–2364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Margison GP and Santibáñez-Koref MF:
O6-alkylguanine-DNA alkyltransferase: role in
carcinogenesis and chemotherapy. Bioessays. 24:255–266. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Håvik AB, Brandal P, Honne H, Dahlback HS,
Scheie D, Hektoen M, Meling TR, Helseth E, Heim S, Lothe RA and
Lind GE: MGMT promoter methylation in gliomas-assessment by
pyrosequencing and quantitative methylation-specific PCR. J Transl
Med. 10:362012. View Article : Google Scholar : PubMed/NCBI
|
